Table 1.
Clinical and biochemical data of all subjects
| Main study | Subsequent study | |||
|---|---|---|---|---|
| Controls, n = 33 | CLD, n = 113 | Controls, n = 16 | CLD, n = 40 | |
| Age (years) | 46 ± 16 (26–82) | 55 ± 12 (23–78) | 62 ± 18 (29–86) | 52 ± 15 (24–74) |
| Gender (male/female) | 21/12 | 37/76 | 9/7 | 18/22 |
| BMI (kg/m2) | 21.7 ± 2.4 (16–26) | 22.7 ± 3.9 (16–37) | 21.8 ± 2.4 (17–25) | 24.0 ± 3.7 (16–35) |
| Presence of ascites (%) | 0 (0) | 12 (11) | 0 (0) | 2 (5) |
| AST (IU/L) | 18.0 ± 3.5 (13–24) | 54.8 ± 51.4 (16–447) | 19.9 ± 5.5 (13–32) | 71.4 ± 53.5 (19–236) |
| ALT (IU/L) | 13.4 ± 5.3 (9–30) | 61 ± 89 (10–867) | 14.6 ± 3.3 (10–19) | 91.7 ± 101 (16–526) |
| Total bilirubin (mg/dL) | 0.87 ± 0.33 (0.4–1.3) | 1.0 ± 1.4 (0.4–15) | 0.6 ± 0.14 (0.5–0.8) | 1.2 ± 2.2 (0.7–1.8) |
| Albumin (g/dL) | 4.5 ± 0.36 (3.9–5.0) | 4.0 ± 0.54 (1.7–5.4) | 4.2 ± 0.3 (3.9–4.8) | 4.3 ± 0.4 (3.2–5.2) |
| Platelets (109/L) | 244 ± 44 (163–340) | 177 ± 70 (44–428) | 227 ± 43 (162–336) | 182 ± 59 (48–320) |
| FIB4 | 1.0 ± 0.61 (0.4–2.6) | 3.0 ± 2.5 (0.40–15) | 1.5 ± 0.7 (0.5–3.0) | 2.8 ± 2.7 (0.7–16) |
| Aetiology, HCV/HBV/AIH/PBC /NASH/Alcohol/ Cryptogenic | – | 62/13/10/13/3/5/7 | – | 15/5/5/5/6/2/2 |
| Activity grade, A0-1/A2/A3 | – | 53/50/10 | – | 21/9/10 |
| Grade of fibrosis, F0/F1/F2/F3/ Cirrhosis | – | 4/31/26/23/29 | – | 1/6/20/7/6 |
| Child-Pugh class, A/B/C | – | 19/9/1 | – | 5/0/1 |
CLD, chronic liver disease; BMI, body mass index; AST, aspartate transaminase; ALT, alanine transaminase; FIB4, age × AST/(Platelet Count/ALT0.5); HCV, hepatitis C virus; HBV, hepatitis B virus; AIH, autoimmune hepatitis; PBC, primary biliary cirrhosis; NASH, non-alcoholic steatohepatitis